Novartis says experimental drug helps chronic migraine sufferers

ZURICH (Reuters) - About 40 percent of chronic migraine sufferers taking an experimental drug developed by Novartis and Amgen saw the number of days they suffered a migraine cut by at least half, beating the placebo in the trial.